Integra Lifesciences Holdings (IART) Receivables - Net (2009 - 2026)

Integra Lifesciences Holdings has disclosed Receivables - Net across 18 years of filings, most recently posting $267.2 million for Q2 2026.

• In Q2 2026, Receivables - Net fell 6.09% year-over-year to $267.2 million; the TTM figure through Jun 2026 stood at $267.2 million (down 6.09% YoY), while the FY2025 annual figure was $278.8 million, up 2.38% from the prior year.
• Receivables - Net came in at $267.2 million for Q2 2026 at Integra Lifesciences Holdings, up from $264.4 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $284.5 million in Q2 2025 to a low of $234.0 million in Q1 2022.
• Average Receivables - Net over 5 years is $258.5 million, with a median of $259.0 million recorded in 2023.
• Year-over-year, Receivables - Net climbed 13.65% in 2022 and declined 6.09% in 2026.
• Over 5 years, Receivables - Net stood at $263.5 million in 2022, then retreated by 1.57% to $259.3 million in 2023, then grew by 5.03% to $272.4 million in 2024, then advanced by 2.38% to $278.8 million in 2025, then slipped by 4.18% to $267.2 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $267.2 million in Q2 2026, $264.4 million in Q1 2026, and $278.8 million in Q4 2025.